Inhibitor Therapeutics seeks FDA guidance after HP2001 finds 0.265 new tumors per patient-year
AI Summary- Inhibitor Therapeutics asked FDA for guidance on itraconazole’s Gorlin Syndrome development program.
- HP2001 recorded 0.265 new surgically eligible tumors per patient-year during treatment.
- FDA classified INTI’s request as Type C and set a written-response goal for September 2026.